Buscar
Mostrando ítems 1-6 de 6
Prevalence of Systemic Lupus Erythematosus in Spain: Higher than Previously Reported in Other Countries?
(Oxford, 2020-01-30)
[Abstract] Objectives: Prevalence of SLE varies among studies, being influenced by study design, geographical area and ethnicity. Data about the prevalence of SLE in Spain are scarce. In the EPISER2016 study, promoted by ...
Cardiovascular disease in immune-mediated inflammatory diseases: a cross-sectional analysis of 6 cohorts
(Wolters Kluwer, 2017-06)
[Abstract] To analyze in several immune-mediated inflammatory diseases (IMIDs) the influence of demographic and clinical-related variables on the prevalence of cardiovascular disease (CVD), and compare their standardized ...
Mitochondrial DNA haplogroups influence the risk of incident knee osteoarthritis in OAI and CHECK cohorts: a meta-analysis and functional study
(BMJ, 2016-12-05)
[Abstract] Objective To evaluate the influence of the mitochondrial DNA (mtDNA) haplogroups in the risk of incident knee osteoarthritis (OA) and to explain the functional consequences of this association to identify potential ...
A Meta-Analysis of Genome-Wide Association Studies Identifies Novel Variants Associated with Osteoarthritis of the Hip
(BMJ, 2013-08-29)
[Abstract] OBJECTIVES:
Osteoarthritis (OA) is the most common form of arthritis with a clear genetic component. To identify novel loci associated with hip OA we performed a meta-analysis of genome-wide association studies ...
Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries?
(Oxford, 2020-01-30)
[Abstract] Objectives: Prevalence of SLE varies among studies, being influenced by study design, geographical area and ethnicity. Data about the prevalence of SLE in Spain are scarce. In the EPISER2016 study, promoted by ...
Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases
(BMJ, 2020-06-12)
[Abstract] Background: The susceptibility of patients with rheumatic diseases and the risks or benefits of immunosuppressive therapies for COVID-19 are unknown.
Methods: We performed a retrospective study with patients ...